Global Bacillus Calmette-Gurin (BCG) Vaccine Market Analysis and Industry Forecast 2017-2023, With an Expected CAGR of 4.6% - ResearchAndMarkets.com

June 8, 2018

DUBLIN--(BUSINESS WIRE)--Jun 8, 2018--The “BCG Vaccine Market by Demographics [Pediatrics] - Global Opportunity Analysis and Industry Forecast, 2017-2023” report has been added to ResearchAndMarkets.com’s offering.

The global BCG vaccine market is estimated to reach $28,051 thousand by 2023, growing at a CAGR of 4.6% from 2017 to 2023, from $20,366 thousand in 2016.

Bacillus Calmette-Gurin (BCG) vaccine is the only vaccine available for prevention of human forms of tuberculosis (TB). This vaccine is generally administered to children at birth in countries with high incidence of TB. In regions with low level of TB, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.

The global BCG vaccine market is driven by increase in prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, the increase in government initiatives and focus on immunization programs globally boost the market growth. However, side effects of BCG vaccine and a global shortage of BCG vaccine restrain this growth. Untapped market potential in developing regions is expected to present numerous opportunities for market development.

Companies Mentioned:

Merck & Co., Inc. Sanofi Pasteur Japan BCG Laboratory China National Biotec Group Serum Institute of India Pvt. Ltd. InterVax Ltd. GreenSignal Bio Pharma Limited (GSBPL) Statens Serum Institut

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Market Overview

Chapter 4 Global BCG Vaccine Market, By Demographics

Chapter 5 BCG Vaccine Market, By Country

Chapter 6 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/n44d4h/global_bacillus?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180608005324/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines,Pediatrics



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/08/2018 08:21 AM/DISC: 06/08/2018 08:21 AM


Update hourly